Oruka Therapeutics Gets IND Clearance for ORKA-001 Psoriasis Trial
Oruka Therapeutics received FDA clearance for its Investigational New Drug (IND) application to begin the Phase 2a clinical trial,...
Oruka Therapeutics received FDA clearance for its Investigational New Drug (IND) application to begin the Phase 2a clinical trial,...
Actuate Therapeutics has completed Phase 1 of its elraglusib study in pediatric patients with refractory cancers, observing promising results...
Lisata Therapeutics and WARPNINE Incorporated completed patient enrollment in their Phase 1b/2a iLSTA trial in Australia. The trial evaluates...
Keros Therapeutics initiated Phase 3 trials for elritercept, a treatment for transfusion-dependent anemia in patients with myelodysplastic syndromes (MDS)....
ImCheck Therapeutics’ lead candidate, ICT01, has received FDA Orphan Drug Designation for the treatment of acute myeloid leukemia (AML)....
OKYO Pharma’s Phase 2 trial of urcosimod for neuropathic corneal pain (NCP) yielded positive top-line results. The trial involved...
Cue Biopharma announced positive clinical updates for CUE-101, its lead drug candidate for recurrent/metastatic head and neck squamous cell...
Cognition Therapeutics announced positive Phase 2 results for zervimesine in treating dementia with Lewy bodies (DLB) at the Alzheimer’s...
Voyager Therapeutics has expanded its Alzheimer’s disease pipeline with a new gene therapy program targeting APOE, the strongest genetic...
Hengrui Pharma and Kailera Therapeutics announced positive topline data from a Phase 3 clinical trial of HRS9531/KAI-9531, a novel...